Sushil Patel, Ph.D. has served on our Board of Directors since June 2022.
Dr. Patel is a seasoned operating executive who brings to our Board substantial experience and perspective on the precision oncology commercial landscape.
Dr. Patel has served as Chief Executive Officer of Replimune Group, Inc., a biotechnology company, since April 2024 and previously served as its Chief Strategy Officer from January 2023 to March 2024 and its Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. from April 2018 to May 2021, and previously held various positions of increasing responsibility at Genentech, Inc. from 2002 to April 2018, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, he was Senior Consultant at Front Line Strategic Management Consulting. Prior to this, Dr. Patel served as a Senior Research Executive at IMS Health in the Pharma Strategy Group from 1996 to 1999 and Clinical Research Scientist at the Central Public Health Laboratory from 1993 to 1996.
He obtained a Ph.D. in Molecular Biology from the University of London in 1999, an M.S. in Biotechnology from the Imperial College London in 1993 and a B.S. in Microbiology and Microbial Technology from the University of Warwick in 1992.
What is Sushil Patel's net worth?
The estimated net worth of Sushil Patel is at least $8.90 million as of December 16th, 2024. Dr. Patel owns 202,014 shares of Revolution Medicines stock worth more than $8,900,737 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Patel may own. Learn More about Sushil Patel's net worth.
How do I contact Sushil Patel?
Has Sushil Patel been buying or selling shares of Revolution Medicines?
Sushil Patel has not been actively trading shares of Revolution Medicines during the last ninety days. Most recently, Sushil Patel sold 2,155 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $44.00, for a transaction totalling $94,820.00. Following the completion of the sale, the director now directly owns 19,948 shares of the company's stock, valued at $877,712. Learn More on Sushil Patel's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 271,841 shares worth more than $11,976,056.91. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 12/16/2024.
